Montpellier – France – July 10th, 2023 – CILcare, a biotechnology company specialized in auditory sciences and research and development of new therapies for inner ear and associated diseases, is announcing the appointment of Alain Chatelin acting as Chief Medical Officer, effective June 19th, 2023. With over 20 years of experience in global drug development, Dr. Chatelin will be responsible for overseeing CILcare’s clinical development and regulatory operations.
“I am delighted to welcome Alain Chatelin to CILcare’s Team”, said Celia BELLINE, CILcare’s CEO. “Alain’s extensive experience in clinical submission and track record in bringing novel medicines to patients will be invaluable as we move towards the Phase 2A clinical trial for our lead compound targeting cochlear synaptopathy.”
Alain Chatelin is a medical doctor who specialized in intensive care and pulmonology and rapidly joined the pharmaceutical industry. He served as Deputy Head of Clinical Operations at Hoechst Marion Roussel, was a board member for BioAlliance Pharma, as well as Chief Medical Officer at Ose Immunotherapeutics, a listed company developing immune-oncology products, where he played a key role in the strategy, direction and execution of the clinical development plans. He is the co-founder of Altius and Co, a consulting agency which specializes in medical & regulatory affairs, clinical research and market access.
In his spare time, he is highly involved in charities, notably as Chairman of a research foundation for childhood-onset neuro-disabilities.
“CILcare’s upcoming clinical development program targeting cochlear synaptopathy and associated diseases is fully aligned with my passion for developing drug candidates in clinical phase. I like finding the right balance between regulatory options in the development of products for unmet medical needs, the confidence given to clinical data, and the key features for attaining goals,” said Alain Chatelin.
About CILcare: CILcare is a biotechnology company harnessing auditory sciences
for the early definition, detection and treatment of synaptopathy in neurocognitive and inflammatory diseases. Located in Montpellier and the Boston area (USA), CILcare develops its own portfolio of drug candidates using its next-generation AI (Artificial Intelligence) and RWD (Real-World Data) platform, relying on unique expertise in preclinical development and on the ability to translate generated data into a clinical development strategy.
CILCARE has also been a catalyzer in accelerating drug development in hearing disorders since 2014 by providing its smart R&D platform as a research-for-hire to some of the top hearing research companies and academic institutions in US, Europe and Asia.